CVI Holdings’s Mersana Therapeutics MRSN Stock Holding History

CVI Holdings’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,359	Closed	-$442K	–	72
2019 Q1	$442K	Buy	+3,359	New	+$423K	0.42%	24

Other funds holding MRSN

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

CVI Holdings's MRSN Position: Q2 2019 in Review

CVI Holdings sold out of Mersana Therapeutics (MRSN) in Q2 2019, closing a stake of 3,359 shares — an estimated $442K sold.

CVI Holdings first reported a position in MRSN in Q1 2019 and held it in 1 quarter. The position peaked at $442K in Q1 2019. 77 funds tracked by Wall St. Rank hold MRSN as of Q2 2019.

CVI Holdings reported no remaining Mersana Therapeutics position as of Q2 2019 after selling out during the quarter.
CVI Holdings sold 3,359 Mersana Therapeutics shares in Q2 2019, an estimated $442K.
CVI Holdings first reported a position in Mersana Therapeutics in Q1 2019 and held it in 1 quarter.
CVI Holdings's Mersana Therapeutics position peaked at $442K in Q1 2019.
77 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2019.

Based on CVI Holdings's 13F filing for Q2 2019, filed 14 Aug 2019.